Literature DB >> 29397482

Somatic NRAS mutation in patient with generalized lymphatic anomaly.

Eugenia Manevitz-Mendelson1, Gil S Leichner1, Ortal Barel2, Inbal Davidi-Avrahami3, Limor Ziv-Strasser2, Eran Eyal2, Itai Pessach4,5, Uri Rimon6, Aviv Barzilai1,4, Abraham Hirshberg7, Keren Chechekes2, Ninette Amariglio4,2, Gideon Rechavi4,2, Karina Yaniv3, Shoshana Greenberger8,9.   

Abstract

Generalized lymphatic anomaly (GLA or lymphangiomatosis) is a rare disease characterized by a diffuse proliferation of lymphatic vessels in skin and internal organs. It often leads to progressive respiratory failure and death, but its etiology is unknown. Here, we isolated lymphangiomatosis endothelial cells from GLA tissue. These cells were characterized by high proliferation and survival rates, but displayed impaired capacities for migration and tube formation. We employed whole exome sequencing to search for disease-causing genes and identified a somatic mutation in NRAS. We used mouse and zebrafish model systems to initially evaluate the role of this mutation in the development of the lymphatic system, and we studied the effect of drugs blocking the downstream effectors, mTOR and ERK, on this disease.

Entities:  

Keywords:  Lymphangiomatosis; Mutation; NRAS

Mesh:

Substances:

Year:  2018        PMID: 29397482     DOI: 10.1007/s10456-018-9595-8

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  12 in total

1.  ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.

Authors:  Dong Li; Michael E March; Alvaro Gutierrez-Uzquiza; Charlly Kao; Christoph Seiler; Erin Pinto; Leticia S Matsuoka; Mark R Battig; Elizabeth J Bhoj; Tara L Wenger; Lifeng Tian; Nora Robinson; Tiancheng Wang; Yichuan Liu; Brant M Weinstein; Matthew Swift; Hyun Min Jung; Courtney N Kaminski; Rosetta Chiavacci; Jonathan A Perkins; Michael A Levine; Patrick M A Sleiman; Patricia J Hicks; Janet T Strausbaugh; Jean B Belasco; Yoav Dori; Hakon Hakonarson
Journal:  Nat Med       Date:  2019-07-01       Impact factor: 53.440

2.  Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

Authors:  Guy Chowers; Gadi Abebe-Campino; Hana Golan; Asaf Vivante; Shoshana Greenberger; Michalle Soudack; Galia Barkai; Ilana Fox-Fisher; Dong Li; Michael March; Mark R Battig; Hakon Hakonarson; Denise Adams; Yoav Dori; Adi Dagan
Journal:  Pediatr Res       Date:  2022-03-04       Impact factor: 3.953

Review 3.  Lymphatic Phenotype of Noonan Syndrome: Innovative Diagnosis and Possible Implications for Therapy.

Authors:  Lotte E R Kleimeier; Caroline van Schaik; Erika Leenders; Maxim Itkin; Willemijn M Klein; Jos M T Draaisma
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

4.  A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

Authors:  Sarah F Barclay; Kyle W Inman; Valerie L Luks; John B McIntyre; Alyaa Al-Ibraheemi; Alanna J Church; Antonio R Perez-Atayde; Shamlal Mangray; Michael Jeng; Sara R Kreimer; Lori Walker; Steven J Fishman; Ahmad I Alomari; Gulraiz Chaudry; Cameron C Trenor Iii; Denise Adams; Harry P W Kozakewich; Kyle C Kurek
Journal:  Genet Med       Date:  2018-12-13       Impact factor: 8.822

5.  Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.

Authors:  Michio Ozeki; Yoko Aoki; Akifumi Nozawa; Shiho Yasue; Saori Endo; Yumiko Hori; Kentaro Matsuoka; Tetsuya Niihori; Ryo Funayama; Matsuyuki Shirota; Keiko Nakayama; Toshiyuki Fukao
Journal:  Orphanet J Rare Dis       Date:  2019-09-11       Impact factor: 4.123

6.  Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.

Authors:  Jason E Fish; Carlos Perfecto Flores Suarez; Emilie Boudreau; Alexander M Herman; Manuel Cantu Gutierrez; Dakota Gustafson; Peter V DiStefano; Meng Cui; Zhiqi Chen; Karen Berman De Ruiz; Taylor S Schexnayder; Christopher S Ward; Ivan Radovanovic; Joshua D Wythe
Journal:  Circ Res       Date:  2020-06-17       Impact factor: 17.367

Review 7.  Recent Progress in Lymphangioma.

Authors:  Xiaowei Liu; Cheng Cheng; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  Front Pediatr       Date:  2021-12-15       Impact factor: 3.418

Review 8.  A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.

Authors:  Guillaume Canaud; Adrienne M Hammill; Denise Adams; Miikka Vikkula; Kim M Keppler-Noreuil
Journal:  Orphanet J Rare Dis       Date:  2021-07-08       Impact factor: 4.123

9.  Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models.

Authors:  Zhenhong Fu; David Mui; Hang Zhu; Ying Zhang
Journal:  Aging (Albany NY)       Date:  2020-05-11       Impact factor: 5.682

10.  KRAS-driven model of Gorham-Stout disease effectively treated with trametinib.

Authors:  Nassim Homayun-Sepehr; Anna L McCarter; Raphaël Helaers; Christine Galant; Laurence M Boon; Pascal Brouillard; Miikka Vikkula; Michael T Dellinger
Journal:  JCI Insight       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.